

# Vitamin K<sub>2</sub> protects against A $\beta$ 42-induced neurotoxicity by activating autophagy and improving mitochondrial function in *Drosophila*

Xiaohui Lin<sup>a,b</sup>, Xueyi Wen<sup>b</sup>, Zaiwa Wei<sup>b</sup>, Keyi Guo<sup>b</sup>, Fang Shi<sup>b</sup>, Tingting Huang<sup>b</sup>, Wenjing Wang<sup>b</sup> and Jinou Zheng<sup>a</sup>

**Objective** Alzheimer disease is characterized by progressive decline in cognitive function due to neurodegeneration induced by accumulation of A $\beta$  and hyperphosphorylated tau protein. This study was conducted to explore the protective effect of vitamin K<sub>2</sub> against A $\beta$ 42-induced neurotoxicity.

**Methods** Alzheimer disease transgenic *Drosophila* model used in this study was amyloid beta with the arctic mutation expressed in neurons. Alzheimer disease flies were treated with vitamin K<sub>2</sub> for 28 days after eclosion. A $\beta$ 42 level in brain was detected by ELISA. Autophagy-related genes and NDUFS3, the core subunit of mitochondrial complex I, were examined using real-Time PCR (RT-PCR) and western blot analysis.

**Results** Vitamin K<sub>2</sub> improved climbing ability ( $P=0.0105$ ), prolonged lifespan ( $P<0.0001$ ) and decreased A $\beta$ 42 levels ( $P=0.0267$ ), upregulated the expression of LC3 and Beclin1 ( $P=0.0012$  and  $P=0.0175$ , respectively), increased the conversion of LC3I to LC3II ( $P=0.0206$ ) and decreased p62 level ( $P=0.0115$ ) in

Alzheimer disease flies. In addition, vitamin K<sub>2</sub> upregulated the expression of NDUFS3 ( $P=0.001$ ) and increased ATP production ( $P=0.0033$ ) in Alzheimer disease flies.

**Conclusion** It seems that vitamin K<sub>2</sub> protect against A $\beta$ 42-induced neurotoxicity by activation of autophagy and rescue mitochondrial dysfunction, which suggests that it may be a potential valuable therapeutic approach for Alzheimer disease. *NeuroReport* 32: 431–437 Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.

*NeuroReport* 2021, 32:431–437

**Keywords** Alzheimer disease, amyloid- $\beta$ , autophagy, *Drosophila*, mitochondria, vitamin K<sub>2</sub>

<sup>a</sup>Department of Neurology, The First Affiliated Hospital of Guangxi Medical University, Nanning and <sup>b</sup>Department of Neurology, The Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, China

Correspondence to Jinou Zheng, MD, Department of Neurology, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021 Guangxi, China  
Tel: +0086 0773 5356504; e-mail: jinouzheng@163.com

Received 12 September 2020 Accepted 8 December 2020

## Introduction

Alzheimer disease is characterized by progressive decline in cognitive function. The pathological features of Alzheimer disease are deposition of amyloid- $\beta$  (A $\beta$ ) and accumulation of hyperphosphorylated tau protein (pTau) [1]. Accumulating evidence demonstrates that autophagy dysfunction is involved in the pathogenesis of Alzheimer disease. The first direct evidence is that Nixon identified immature autophagy vacuoles accumulated in dystrophic neurons in Alzheimer disease brains [2]. Studies also found that downregulated expressions of some autophagy-related genes occurred in Alzheimer disease, resulting in autophagy dysfunction and reducing the clearance of A $\beta$  [3].

Mitochondria are the main site of ATP production and are considered as ‘powerhouses’ of cells. Many studies have confirmed that mitochondrial dysfunction is involved in Alzheimer disease. In 2004, Swerdlow and Khan [4] proposed a ‘mitochondrial cascade hypothesis’, which declared that mitochondrial dysfunction results in ATP production decline and excessive reactive oxygen species production, which lead to the formulation of A $\beta$  plaques and neurofibrillary tangles. In return, A $\beta$  and pTau interfered with enzyme metabolism and the dynamic system of mitochondria [5]. In addition, autophagy dysfunction leads to reducing the clearance of damaged mitochondria and subsequent accumulation in cells, which in return exacerbates mitochondrial damage [6]. Therefore, a ‘vicious cycle’ was formed among mitochondrial dysfunction, A $\beta$  deposition and autophagy dysfunction.

Vitamin K<sub>2</sub> generates from the activity of intestinal bacteria or the conversion of dietary vitamin K<sub>1</sub> [7]. It has been reported that vitamin K<sub>2</sub> has a variety of biological functions, including anti-inflammation [8], antioxidant stress, antiapoptosis [9], stimulating autophagy [10] and serves as a mitochondrial electron carrier during oxidative respiration [11].

Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website, [www.neuroreport.com](http://www.neuroreport.com).

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Therefore, based on the pathogenesis of Alzheimer disease and the pharmacological effects of vitamin K<sub>2</sub>, we hypothesized that vitamin K<sub>2</sub> has a protective effect on Alzheimer disease. A study *in vitro* preliminary has shown that vitamin K<sub>2</sub> reduces the Aβ-induced cytotoxicity and improves cell survival [8]. In this study, we set out to establish Alzheimer disease transgenic *Drosophila* to further demonstrate the protective effect of vitamin K<sub>2</sub> and explore its neuroprotective mechanism *in vivo*.

## Materials and methods

### Animal strains

*Drosophila* was cultured on standard medium at 25 °C. The *drosophila* strains used in this study included: *P{UAS-Aβarc}* (line for expressing arctic mutant human Aβ42) [12] and wild-type *w1118* and *[GAL4]A307* (drives expression in the giant fiber system). *P{UAS-Aβarc}* line was crossed to *[GAL4]A307* line to receive male filial generation 1(F1) *drosophilas* expressing arctic mutant Aβ42 in the giant fiber system, *[GAL4]A307{UAS-Aβarc}*, which were used for the next series of experiments.

### Vitamin K<sub>2</sub> treatment paradigm

Vitamin K<sub>2</sub> (Sigma, Saint Louis, Missouri, USA) was dissolved in anhydrous ethanol to obtain a 0.4M stock solution. According to different concentrations, the flies were divided into five groups: ①wild-type *A307/w1118*, no treatment with K<sub>2</sub>, ②*A307/Aβarc*, no treatment with K<sub>2</sub>, ③*A307/Aβarc* + 0.1 mM K<sub>2</sub>, treated with vitamin K<sub>2</sub> at 0.1 mM, ④*A307/Aβarc* + 0.5 mM K<sub>2</sub>, treated with vitamin K<sub>2</sub> at 0.5 mM and ⑤*A307/Aβarc* + 0.8 mM K<sub>2</sub>, treated with vitamin K<sub>2</sub> at 0.8 mM. A total of 100 μL vitamin K<sub>2</sub> solution was added into each vial containing 20 flies daily until 28 days. The flies were transferred into fresh food every 7 days.

### Fly behavioral assays

#### Fly climbing ability

The automatic iterative negative geotaxis (RING) assay was used to detect the fly climbing ability [13]. About 80 flies from each group were divided into different testing tubes. Flies were automatically tapped four consecutive times by the RING apparatus to fell to the bottom of the tubes. Then flies began to climb up along the walls. The climbing behavior of flies was recorded by a digital video. The above process was repeated three times by 1 min intervals. The height of each fly at the tenth second was measured by software RflyDetection2.0 [13], and the average value of three trials was obtained to evaluate the fly climbing ability.

#### Longevity assay

A total of 80 flies from each group was equally distributed to four vials containing standard fly food and incubated at 25 °C. The food vials were replaced every 3 days and the dead flies were counted until all the flies died. Survival curves were analyzed with the GraphPad Prism 8 software. Fly behavioral assays provided the basis for

selecting the optimal concentration of K<sub>2</sub> for the following assessments.

### Aβ42 detection by ELISA

After dissected on the ice, 30 heads of flies from each group were immediately placed into 50 μL cold ELISA sample buffer containing cocktail protease inhibitors. The heads were thoroughly homogenized and incubated at room temperature for 4h. The supernatant was collected after centrifugation at 12000×g and 4 °C for 10 min. A total of 3 μL supernatant was diluted to 60 μL with standard dilution buffer, and 50 μL diluent was taken for ELISA. According to the manufacturer's instructions, detection of Aβ42 levels was performed using the Aβ42 Human ELISA Kit (Invitrogen, catalog number KHB3441, Carlsbad, California, USA).

### Real-time fluorescent quantitative PCR analysis


We used Trizol to extract total RNA. RNA concentration was measured with NanoDrop 2000 (Thermo Scientific, Waltham, Massachusetts, USA). PrimeScript™ II 1st Strand cDNA Synthesis Kit (TaKaRa, Japan) was used to synthesis cDNA. The sequence of the forward and reverse primers is listed as follows: LC3 Fw primer: 5'-AGGATGCCCTCTTCTTCTTTG-3', Rev primer: 5'-GAAATAGT CCTCCTCGT GATGTT-3'; Beclin1 Fw primer: 5'-ACAGGAACGACAATGAGT GAG-3', Rev primer: 5'-TC CGTAGATGGGCAAAGATAAC-3'; NADH dehydrogenase (ubiquinone) ferrithionein 3(NDUFS3) Fw primer: 5'-GCTCG CATCTCTCCGATT-3', Rev primer: 5'-AATAAGCACCTCCAGCTCATC-3'.

The real-Time PCR (RT-PCR) reaction system included: 4ng cDNA, 5pmol primer, 5μL Power SYBR Green Master Mix (Thermo Fisher Scientific, USA), 3μLR-Nase Freed H<sub>2</sub>O. SYBR Green was used to detect double-stranded DNA. The PCR amplification was carried out using Applied Biosystems device (7500Fast RT-PCR system, Thermo Fisher Scientific) under the following conditions: 40 cycles of 10 min at 95 °C, 15 s at 95 °C and 1 min at 60 °C. 18s acted as an endogenous control for data normalization. Relative mRNA expression was determined by the 2<sup>-ΔΔC<sub>q</sub></sup> method [14]. Relative quantitative analysis of data was conducted with the GraphPad Prism 8 software.

### Western blotting

For extracting total protein, 30 heads of flies from each group were homogenized and lysed in RIPA and 1:100 inhibitor proteases and inhibitor phosphatases cocktail (Thermo Fisher Scientific). For each group, a total of 30 μg protein was separated using 12% SDS-PAGE and transferred to a polyvinylidene fluoride membrane. After incubated in 5% BSA (Solarbio, China) at room temperature for 2h, the membranes were incubated with primary antibodies against β-actin, LC3(Abcam, England), P62(Abcam, England) and NDUFS3(Abcam, England)

Fig. 1



Improvement of climbing ability and lifespan in Alzheimer disease flies by vitamin K<sub>2</sub>. (a) Analysis of the climbing ability using aRING assay in different groups of flies, one-way ANOVA using Dunnett's test; \*\* $P < 0.01$  vs. A307/W1118; #  $P < 0.05$  vs. A307/Aβarc. (b) The lifespan in different groups of flies,  $n = 80$  flies for each line, log-rank test, compared with A307/Aβarc flies,  $P < 0.05$  for A307/Aβarc + 0.1 mM K<sub>2</sub> and A307/Aβarc + 0.5 mM K<sub>2</sub> flies was  $P < 0.05$  and  $P < 0.001$ , respectively. (c) ELISA analysis human Aβ<sub>42</sub> level, one-way ANOVA using Dunnett's test; #  $P < 0.05$  vs. A307/Aβarc. As expected, the A307/W1118 flies did not express human Aβ<sub>42</sub>. ANOVA, analysis of variance.

overnight at 4 °C. After washed with TBST, the membrane was incubated with horseradish peroxidase-conjugated antirabbit or antimouse for 1 h at room temperature. Bands were visualized using an electro-chemi-Luminescence chemiluminescence kit (Thermo Fisher Scientific) on BIO-RAD ChemiDoc™ XRS+ system (USA), and then the grayscale value of bands were scanned with the Image J software.

#### ATP measurements

A total of 15 heads of flies from each group was homogenized in 1.5 mL pyrolysis liquid. The ATP content was measured according to the manufacturer's instructions of the ATP Determination Kit (Beyotime, China). ATP concentrations were determined with TECAN infinite F500 (Switzerland).

#### Statistical analyses


All data were expressed as mean ± SD. Statistical significance was set at  $P \leq 0.05$ . All statistical analyses were performed using GraphPad Prism 8 software. One-way analysis of variance was used for statistical significance and followed by Dunnett's post hoc test for comparison between every two groups.

#### Results

##### Effects of vitamin K<sub>2</sub> on the behavior of Alzheimer disease flies


The automatic RING assay revealed that the climbing ability of A307/Aβarc flies declined compared to wild-type A307/w1118 flies at the same age. This Aβ<sub>42</sub>-induced locomotor defect was ameliorated by different concentrations of vitamin K<sub>2</sub> (from 0.1 to 0.8 mM), but a

Fig. 2



Effects of vitamin K<sub>2</sub> on autophagy-related genes. (a,b) Normalized quantification of the LC3 and Beclin1 mRNA in flies, one-way ANOVA using Dunnett's test, compared with A307/Aβarc flies. *P* for A307/Aβarc + 0.5 mM K<sub>2</sub> flies was ##*P*<0.05, and #*P*<0.01, respectively. (c,d) Western blot and quantitative analysis show that LC3II/LC3I ratio level were higher in the A307/Aβarc + 0.5 mM K<sub>2</sub> flies compared to A307/Aβarc flies (#*P*<0.05), and p62 level decreased in the A307/Aβarc + 0.5 mM K<sub>2</sub> flies compared to A307/Aβarc flies (#*P*<0.05). ANOVA, analysis of variance.

Fig. 3



Vitamin K<sub>2</sub> increased the ATP level. The supernatant from the brain homogenate was used to assay the ATP level, one-way ANOVA using Dunnett's test, \*\* $P < 0.01$  vs. A307/W1118, ## $P < 0.01$  vs. A307/Aβarc. ANOVA, analysis of variance.

significant difference was only shown in the 0.5 mM concentration ( $P = 0.0105$ ) (Fig. 1a).

The lifespan of the A307/Aβarc flies was shorter than that of A307/w1118 flies. Vitamin K<sub>2</sub> (0.1–0.8 mM) prolonged lifespan of Alzheimer disease flies; significant difference was both shown in the 0.1 mM and 0.5 mM concentration ( $P = 0.0097$  and  $P < 0.0001$ , respectively) (Fig 1b).

Based on the above data, the 0.5 mM concentration of vitamin K<sub>2</sub> was used as optimal concentration for the following experiments.

ELISA analysis revealed that treatment with vitamin K<sub>2</sub> markedly decreased Aβ<sub>42</sub> level ( $P = 0.0267$ ) (Fig. 1c).

#### Effects of vitamin K<sub>2</sub> on autophagy-related gene

To investigate the effects of vitamin K<sub>2</sub> on autophagy, LC3, Beclin1 and p62 were detected. RT-PCR analysis showed that treatment with vitamin K<sub>2</sub> significantly increased LC3 and Beclin1 ( $P = 0.0012$  and  $P = 0.0175$ , respectively) (Fig. 2).

Western blot (WB) analysis showed that treatment with vitamin K<sub>2</sub> increased the conversion of LC3 I to LC3 II ( $P = 0.0206$ ) and decreased p62 level ( $P = 0.0115$ ) (Fig. 2). The above data revealed that vitamin K<sub>2</sub> can activate autophagy.

#### Vitamin K<sub>2</sub> rescued mitochondrial dysfunction

To assess the effect of vitamin K<sub>2</sub> on mitochondria, we have measured ATP production and NDUFS3. We found that the ATP level of A307/Aβarc flies were significantly lower than that of A307/W1118 flies ( $P = 0.0013$ ).

Treatment with vitamin K<sub>2</sub> significantly increased the ATP level ( $P = 0.0033$ ) (Fig. 3).

NDUFS3, the core subunit of mitochondrial complex I, participates in the electron transport of the oxidized respiratory chain. RT-PCR and WB revealed that the expression of NDUFS3 declined in A307/Aβarc flies, and vitamin K<sub>2</sub> upregulated the expression of NDUFS3 (Fig. 4).

#### Discussion


In this study, we explored the neuronal protective effects of vitamin K<sub>2</sub> on Alzheimer disease flies. The results showed that vitamin K<sub>2</sub> improved locomotor abilities, prolonged lifespan and significantly decreased Aβ<sub>42</sub> level. Further studies showed that vitamin K<sub>2</sub> increased the LC3II/LC3I ratio and decreased the p62 level. Moreover, vitamin K<sub>2</sub> upregulated the expression of NDUFS3 and increased the ATP level.

The transgenic *Drosophila* Alzheimer disease model used in this study was [Gal4]A307/P{UAS-Aβarc}. Previous studies have confirmed that compared to wild-type, the climbing ability of A307/Aβarc flies declined and the lifespan shortened [15]. In this study, we obtained the same results. This Aβ<sub>42</sub>-induced behavioral defect was ameliorated by vitamin K<sub>2</sub>.

Autophagy is crucial for clearing abnormal proteins in neurodegenerative disorders. Aβ oligomers detected in purified intact autophagosomes confirmed that autophagy plays a direct role in the clearance of Aβ [15]. In the autophagy–lysosomal pathway, the role of LC3 II is to promote phagophore elongation and closure to form a complete autophagosome [16]. Beclin1 plays a key role in the initiation of autophagosome and autophagy regulation [17]. Thus, LC3-II and Beclin1 have been regarded as autophagy markers. P62 plays an important role in the degradation of abnormal protein through two of its functional domains including the ubiquitin-associated domain and LC3-interaction region [18]. P62 aggregates containing autophagy substrates are degraded by proteolytic enzymes in the lysosome; therefore, an increased p62 level reflects lysosome dysfunction. In this study, Alzheimer disease flies showed autophagy dysfunction. Vitamin K<sub>2</sub> increased the LC3II/LC3I ratio and Beclin1 level and decreased the p62 level. These findings suggested that vitamin K<sub>2</sub> can activate autophagy and maintain autophagy flow, which could contribute to the clearance of Aβ, and thereby reduce the Aβ-induced neurotoxicity. Previous studies have demonstrated that activation of autophagy by different strategies, including genetic intervention, pharmacological intervention and physiological intervention, could reduce Aβ deposition, ameliorate pathological phenotypes and rescue cognitive deficits in Alzheimer disease [19–21].

On the basis of the previous studies, we speculated that the possible mechanisms of vitamin K<sub>2</sub> inducing

Fig. 4



Vitamin K<sub>2</sub> increased NDUFS3 expression. (a) Normalized quantification of the NDUFS3 mRNA in flies, one-way ANOVA using Dunnett's test, \* $P < 0.05$  vs. A307/W1118, # $P < 0.05$  vs. A307/Aβarc. (b) Western blot and quantitative analysis show the NDUFS3 level in flies, one-way ANOVA using Dunnett's test, \*\* $P < 0.05$  vs. A307/W1118, ## $P < 0.05$  vs. A307/Aβarc. ANOVA, analysis of variance.

Aβ<sub>42</sub>-affected autophagy may include: first, electron microscopy revealed the formation of autophagosomes and autolysosomes increased in K<sub>2</sub>-treated leukemia cells [22], &&which indicated that vitamin K<sub>2</sub> treatment could activate autophagy. Second, Aβ can be removed by Aβ degrading enzymes, autophagy and blood–brain barrier (BBB) transport in the brain [23]. Vitamin K<sub>2</sub> may promote Aβ clearance by upregulating the mRNA expression of insulin degrading enzyme and NEP1, the Aβ degradation enzymes (Supplementary Data Fig. 5, Supplemental digital content 1, <http://links.lww.com/WNR/A618>). Transport of Aβ through BBB from brain to blood is mainly mediated by receptors such as low-density lipoprotein receptor (LDLR) and low-density lipoprotein receptor-related protein-1 (LRP1) [24,25]. A study found that MK-4 increased the gene expression of LDLR and

LRP1 [26]. So we speculated that vitamin K<sub>2</sub> may promote the transport of Aβ through BBB by increasing LDLR and LRP1 expression. Therefore, vitamin K<sub>2</sub> may eliminate the effect of Aβ on autophagy by promoting Aβ clearance. In addition, further research is needed to investigate the effects of vitamin K<sub>2</sub> on the mechanisms of autophagy regulation, such as the effects of vitamin K<sub>2</sub> on the mTOR/TOR pathway and PI3K-Beclin1 pathway.

It has been confirmed that mitochondrial dysfunction is involved in Alzheimer disease. 'Mitochondrial cascade hypothesis' states that mitochondrial dysfunction can promote amyloid precursor protein processing towards Aβ production and accumulation, and then trigger amyloid cascade [27]. On the other hand, Aβ accumulation adversely accelerate mitochondrial dysfunction [28,29].

In this study, we found that the expression of NDUFS3 declined in Alzheimer disease flies, which directly affected electron transport of mitochondria oxidize respiratory chain, resulting in reduction of ATP production. Vitamin K<sub>2</sub> could increase the expression of NDUFS3 and ATP levels, which suggests that vitamin K<sub>2</sub> has a protective effect on mitochondria.

According to our findings and previous reports, we speculated that the mechanisms of vitamin K<sub>2</sub> rescue mitochondrial dysfunction may include: first, vitamin K<sub>2</sub> serves as electron carrier to transfer electrons in the mitochondrial respiratory chain, increase mitochondrial membrane potential and promote more ATP production [11]. Second, vitamin K<sub>2</sub> upregulates the expression of NDUFS3, which directly enhances electron transport. Third, vitamin K<sub>2</sub> may promote the clearance of damaged mitochondria by activating autophagy.

### Conclusion

In conclusion, this study revealed that Aβ<sub>42</sub> may induce neurotoxicity by damaging autophagy and mitochondrial function. The protective effects of vitamin K<sub>2</sub> against Aβ<sub>42</sub> may be through activating autophagy and improving mitochondrial function. Therefore, vitamin K<sub>2</sub> may be a potentially valuable therapeutic approach for Alzheimer disease.

### Acknowledgements

The authors thank Dr. Fu-De Huang, Chinese Academy of Sciences for donating *P{UAS-Aβarc}* and *[GAL4]A307* fly strains. This study was supported by the Natural Science Foundation of Guangxi Province (CN) [grant numbers 2018GXNSFAA138110]. Animal strains used in this study are *Drosophila*.

### Conflicts of interest

There are no conflicts of interest.

### References

- 1 Yee A, Tsui NB, Chang YN, Au CS, Fok M, Lau LT, *et al.* Alzheimer's disease: insights for risk evaluation and prevention in the Chinese population and the need for a comprehensive programme in Hong Kong/China. *Hong Kong Med J* 2018; **24**:492–500.
- 2 Nixon RA, Wegiel J, Kumar A, Yu WH, Peterhoff C, Cataldo A, Cuervo AM. Extensive involvement of autophagy in Alzheimer disease: an immunoelectron microscopy study. *J Neuropathol Exp Neurol* 2005; **64**:113–122.
- 3 Lachance V, Wang Q, Sweet E, Choi I, Cai CZ, Zhuang XX, *et al.* Autophagy protein NRBF2 has reduced expression in Alzheimer's brains and modulates memory and amyloid-beta homeostasis in mice. *Mol Neurodegener* 2019; **14**:43.
- 4 Swerdlow RH, Khan SM. A "mitochondrial cascade hypothesis" for sporadic Alzheimer's disease. *Med Hypotheses* 2004; **63**:8–20.
- 5 Lu MH, Zhao XY, Yao PP, Xu DE, Ma QH. The mitochondrion: a potential therapeutic target for Alzheimer's disease. *Neurosci Bull* 2018; **34**:1127–1130.
- 6 Kerr JS, Adriaanse BA, Greig NH, Mattson MP, Cader MZ, Bohr VA, Fang EF. Mitophagy and Alzheimer's disease: cellular and molecular mechanisms. *Trends Neurosci* 2017; **40**:151–166.
- 7 Ferland G. Vitamin K and brain function. *Semin Thromb Hemost* 2013; **39**:849–855.
- 8 Saputra WD, Aoyama N, Komai M, Shirakawa H. Menaquinone-4 suppresses lipopolysaccharide-induced inflammation in MG6 mouse microglia-derived cells by inhibiting the NF-κB Signaling pathway. *Int J Mol Sci* 2019; **20**:E2317.
- 9 Hadipour E, Tayarani-Najaran Z, Fereidoni M. Vitamin K2 protects PC12 cells against Aβ (1-42) and H<sub>2</sub>O<sub>2</sub>-induced apoptosis via p38 MAP kinase pathway. *Nutr Neurosci* 2018; **30**:1–10.
- 10 Miyazawa S, Moriya S, Kokuba H, Hino H, Takano N, Miyazawa K. Vitamin K2 induces non-apoptotic cell death along with autophagosome formation in breast cancer cell lines. *Breast Cancer* 2020; **27**:225–235.
- 11 Vos M, Esposito G, Edirisinghe JN, Vilain S, Haddad DM, Slabbaert JR, *et al.* Vitamin K2 is a mitochondrial electron carrier that rescues pink1 deficiency. *Science* 2012; **336**:1306–1310.
- 12 Alisi L, Cao R, De Angelis C, Cafolla A, Caramia F, Cartocci G, *et al.* The relationships between Vitamin k and cognition: a review of current evidence. *Front Neurol* 2019; **10**:239.
- 13 Liu H, Han M, Li Q, Zhang X, Wang WA, Huang FD. Automated rapid iterative negative geotaxis assay and its use in a genetic screen for modifiers of Aβ(42)-induced locomotor decline in *Drosophila*. *Neurosci Bull* 2015; **31**:541–549.
- 14 Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 2001; **25**:402–408.
- 15 Zhao XL, Wang WA, Tan JX, Huang JK, Zhang X, Zhang BZ, *et al.* Expression of beta-amyloid induced age-dependent presynaptic and axonal changes in *Drosophila*. *J Neurosci* 2010; **30**:1512–1522.
- 16 Bernard A, Klionsky DJ. Defining the membrane precursor supporting the nucleation of the phagophore. *Autophagy* 2014; **10**:1–2.
- 17 Hill SM, Wrobel L, Rubinsztein DC. Post-translational modifications of Beclin 1 provide multiple strategies for autophagy regulation. *Cell Death Differ* 2019; **26**:617–629.
- 18 Lin X, Li S, Zhao Y, Ma X, Zhang K, He X, Wang Z. Interaction domains of p62: a bridge between p62 and selective autophagy. *DNA Cell Biol* 2013; **32**:220–227.
- 19 Rocchi A, Yamamoto S, Ting T, Fan Y, Sadleir K, Wang Y, *et al.* A Becl1 mutation mediates hyperactive autophagic sequestration of amyloid oligomers and improved cognition in Alzheimer's disease. *Plos Genet* 2017; **13**:e1006962.
- 20 Vegh C, Pupulin S, Wear D, Culmone L, Huggard R, Ma D, Pandey S. Resumption of autophagy by Ubisul-Q10 in presenilin-1 mutated fibroblasts and transgenic AD mice: implications for inhibition of senescence and neuroprotection. *Oxid Med Cell Longev* 2019; **2019**:7404815.
- 21 Liu Y, Zhou H, Yin T, Gong Y, Yuan G, Chen L, Liu J. Quercetin-modified gold-palladium nanoparticles as a potential autophagy inducer for the treatment of Alzheimer's disease. *J Colloid Interface Sci* 2019; **552**:388–400.
- 22 Yokoyama T, Miyazawa K, Naito M, Toyotake J, Tauchi T, Itoh M, *et al.* Vitamin K2 induces autophagy and apoptosis simultaneously in leukemia cells. *Autophagy* 2008; **4**:629–640.
- 23 Xin SH, Tan L, Cao X, Yu JT, Tan L. Clearance of amyloid beta and tau in Alzheimer's disease: from mechanisms to therapy. *Neurotox Res* 2018; **34**:733–748.
- 24 Cai Z, Qiao PF, Wan CQ, Cai M, Zhou NK, Li Q. Role of blood-brain barrier in Alzheimer's disease. *J Alzheimers Dis* 2018; **63**:1223–1234.
- 25 Yao L, Gu X, Song Q, Wang X, Huang M, Hu M, *et al.* Nanoformulated alpha-mangostin ameliorates Alzheimer's disease neuropathology by elevating LDLR expression and accelerating amyloid-beta clearance. *J Control Release* 2016; **226**:1–14.
- 26 Rønning SB, Pedersen ME, Berg RS, Kirkhus B, Rødbotten R. Vitamin K2 improves proliferation and migration of bovine skeletal muscle cells *in vitro*. *PLoS One* 2018; **13**:e0195432.
- 27 Swerdlow RH, Burns JM, Khan SM. The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives. *Biochim Biophys Acta* 2014; **1842**:1219–1231.
- 28 Casley CS, Canevari L, Land JM, Clark JB, Sharpe MA. Beta-amyloid inhibits integrated mitochondrial respiration and key enzyme activities. *J Neurochem* 2002; **80**:91–100.
- 29 Hou Y, Ghosh P, Wan R, Ouyang X, Cheng H, Mattson MP, Cheng A, *et al.* Permeability transition pore-mediated mitochondrial superoxide flashes mediate an early inhibitory effect of amyloid beta1-42 on neural progenitor cell proliferation. *Neurobiol Aging*. 2014; **35**:975–989.